Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Chief Operating Officer | September 03, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-03 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. Row 2 · 2026-09-03 · Sale · Disposed 10,000 · Balance 0 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.95 · Expires 2029-03-19 | Direct | 104,954 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Exercise / conversion · Disposed 10,000 · Balance 104,954 F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2021 Filed Nov 16, 2021 00:54 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 41,638 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001209191-21-064588 · doc4.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,638 Underlying: Common Stock · 41,638 shares Expires 2031-11-11 F1 · derivative.exercise_date: The option will start to vest one year from November 12, 2021 and then will vest in substantially equal quarterly installments over three years such that the option will be fully vested on November 12, 2025. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 22,163 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010807 · doc4.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,163 Underlying: Common Stock · 22,163 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 41,638 | $0.00 Strike: $65.02 | $0.00 |
DisclosureSEC source: 0000899243-21-010807 · doc4.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,638 Underlying: Common Stock · 41,638 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 5, 2025. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 18,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004010 · edgar.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,645 Underlying: Common Stock · 18,645 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,880 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001179110-20-004010 · edgar.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,880 Underlying: Common Stock · 60,880 shares Expires 2030-03-16 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024. Read SEC document |
| March 17, 2020 Filed Dec 23, 2020 23:08 UTC Amendment | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 14,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-139275 · tm2039202-2_4seq1.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,767 Underlying: Common Stock · 14,767 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 17, 2020 Filed Dec 23, 2020 23:08 UTC Amendment | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 48,237 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001104659-20-139275 · tm2039202-2_4seq1.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,237 Underlying: Common Stock · 48,237 shares Expires 2030-03-16 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.